PDT Partners’s Neurogene NGNE Stock Holding History

PDT Partners’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-562	Closed	-$21K	–	1089
2022 Q1	$21K	Sell	562 -1,411	-72%	-$82.3K	﹤0.01%	909
2021 Q4	$190K	Buy	1,973 +934	+90%	+$114K	0.01%	772
2021 Q3	$150K	Buy	+1,039	New	+$159K	0.01%	714

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PDT Partners's NGNE Position: Q2 2022 in Review

PDT Partners sold out of Neurogene (NGNE) in Q2 2022, closing a stake of 562 shares — an estimated $21K sold.

PDT Partners first reported a position in NGNE in Q3 2021 and held it in 3 quarters. The position peaked at $190K in Q4 2021. 63 funds tracked by Wall St. Rank hold NGNE as of Q2 2022.

PDT Partners reported no remaining Neurogene position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 562 Neurogene shares in Q2 2022, an estimated $21K.
PDT Partners first reported a position in Neurogene in Q3 2021 and held it in 3 quarters.
PDT Partners's Neurogene position peaked at $190K in Q4 2021.
63 funds tracked by Wall St. Rank held Neurogene as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.